- Home
- EUDA vs CUE Comparison
EUDA vs CUE Comparison
Compare EUDA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EUDA
- CUE
- Stock Information
- Founded
- EUDA 2021
- CUE 2014
- Country
- EUDA Singapore
- CUE United States
- Employees
- EUDA N/A
- CUE N/A
- Industry
- EUDA Blank Checks
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- EUDA Finance
- CUE Health Care
- Exchange
- EUDA Nasdaq
- CUE Nasdaq
- Market Cap
- EUDA 68.7M
- CUE 61.1M
- IPO Year
- EUDA N/A
- CUE 2018
- Fundamental
- Price
- EUDA $2.70
- CUE $0.58
- Analyst Decision
- EUDA
- CUE Strong Buy
- Analyst Count
- EUDA 0
- CUE 2
- Target Price
- EUDA N/A
- CUE $3.00
- AVG Volume (30 Days)
- EUDA 79.9K
- CUE 385.4K
- Earning Date
- EUDA 01-01-0001
- CUE 11-12-2025
- Dividend Yield
- EUDA N/A
- CUE N/A
- EPS Growth
- EUDA N/A
- CUE N/A
- EPS
- EUDA 0.01
- CUE N/A
- Revenue
- EUDA $5,160,280.00
- CUE $7,100,000.00
- Revenue This Year
- EUDA $137.25
- CUE N/A
- Revenue Next Year
- EUDA $361.43
- CUE N/A
- P/E Ratio
- EUDA $382.81
- CUE N/A
- Revenue Growth
- EUDA 83.73
- CUE N/A
- 52 Week Low
- EUDA $1.03
- CUE $0.54
- 52 Week High
- EUDA $6.30
- CUE $1.75
- Technical
- Relative Strength Index (RSI)
- EUDA 48.97
- CUE 33.13
- Support Level
- EUDA $2.82
- CUE $0.57
- Resistance Level
- EUDA $3.10
- CUE $0.82
- Average True Range (ATR)
- EUDA 0.32
- CUE 0.08
- MACD
- EUDA -0.02
- CUE -0.01
- Stochastic Oscillator
- EUDA 45.27
- CUE 8.11
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.